Sandoz settles pricing suits with Florida, California

Novartis' ($NVS) generics unit Sandoz has agreed to pay $150 million to settle pricing-fraud lawsuits filed by the states of Florida and California. It's the latest settlement in ongoing probes of average wholesale pricing in the pharma industry. Report

Suggested Articles

California CDMO JSR Life Sciences is building a new home for two subsidiaries as it hopes to enter the competitive biologics market.

Provention Bio wants to connect the familial threads around Type 1 diabetes with two new campaigns—one targeted at doctors and the other at consumers.

Three facts about how distributors are managing in-demand inventory.